Compass Therapeutics Initiated With a Buy at D. Boral Capital
Compass Therapeutics Initiated at Buy by D. Boral Capital
Compass Therapeutics Price Target Announced at $32.00/Share by D. Boral Capital
Compass Point Initiates Coverage On NCR Atleos With Buy Rating, Announces Price Target of $57
Compass Point Downgrades Innovative Ind Props to Neutral, Lowers Price Target to $78
American Express Price Target Raised to $325.00/Share From $315.00 by Compass Point
Compass Point Adjusts Price Target on American Express to $325 From $315, Keeps Neutral Rating
Compass Minerals Intl Analyst Ratings
BMO Capital Maintains Market Perform on Compass Minerals Intl, Lowers Price Target to $18
Needham Maintains Compass(COMP.US) With Buy Rating, Raises Target Price to $10
FTAI Aviation Is Maintained at Buy by Compass Point
Compass Point Maintains Buy on FTAI Aviation, Raises Price Target to $181
Compass Point Upgrades Horizon Tech Finance to Neutral, Announces $8.25 Price Target
Boston Properties (BXP) Gets a Buy From Compass Point
Compass Is Maintained at Equal-Weight by Barclays
Compass Analyst Ratings
Barclays Maintains Compass(COMP.US) With Hold Rating, Raises Target Price to $7
Cullen/Frost Bankers Price Target Raised to $145.00/Share From $122.00 by Compass Point
Cullen/Frost Bankers Is Maintained at Neutral by Compass Point
Compass Point Maintains Buy on BankUnited, Raises Price Target to $49